Articles tagged with Ovarian Cancer
Researchers have found that combining the monoclonal antibody C225 with photodynamic therapy in a mouse model of ovarian cancer resulted in substantial tumor reduction and improved survival rates compared to single-agent treatments. This innovative approach may provide new hope for women diagnosed with this aggressive form of cancer.
African American women face unique genetic challenges in breast cancer screening due to limited data on mutations. Research confirms that genetic testing models work just as well for African Americans as they do for other populations, but the spectrum of mutations is vastly different.
A study by Mayo Clinic researchers found that radical surgery significantly improves five-year survival rates for patients with ovarian cancer and diaphragm disease. The procedure resulted in a 55% survival rate compared to 28% for those who did not undergo surgery.
The new center aims to develop nanomaterials and nanodevices for cancer diagnostics, therapeutics, drug delivery, imaging, and monitoring applications. Researchers will focus on developing early detection tools, targeting cancer cells with chemotherapeutic agents, and creating new classes of drugs.
Researchers have found a surge in Rsf-1 gene copies in 13.2% of high-grade ovarian cancers, but not in low-grade or benign tumors. The amplification is associated with poorer survival rates, and the Hopkins scientists are working to develop targeted therapies.
A study found that a thorough family history is an effective measure for cancer risk, with 20% of women with breast or ovarian cancer having a high risk of BRCA1/BRCA2 mutations. Women of Ashkenazi ancestry were more likely to have high-risk family histories than those of non-Ashkenazi ancestry.
A new protocol has been developed to identify women with high-risk family histories of breast or ovarian cancer, allowing for more accurate data collection and analysis. The study found that 20.6% of participants had elevated risk levels, with higher rates among those with Ashkenazi Jewish ancestry.
A study of 199 families with multiple cases of breast cancer found that women from these families do not have an increased risk of ovarian cancer. Despite this, the genetic mechanism for up to half of hereditary breast cancer remains unknown, prompting ongoing research at Memorial Sloan Kettering Cancer Center.
The US Task Force does not recommend routine screening for breast cancer gene mutations in women without a specific family medical history. However, they do suggest screening for women with a history of Ashkenazi Jewish descent, young-onset breast cancer, or multiple relatives with breast and ovarian cancer.
A study found that the BRCA2 gene mutation significantly increases cancer risk in men, with higher rates of prostate, pancreatic, pharyngeal and bone cancers. The mutation is associated with an increased risk of developing these cancers, particularly among younger men.
Researchers discovered a potential biomarker, PKCi, which predicts outcome in non-serous ovarian cancer when combined with Cyclin E. High levels of the protein correspond to reduced survival rates.
Researchers found that women with ovarian cancer were more likely to present to physicians with abdominal swelling or pelvic pain up to 12 months before diagnosis. Diagnostic testing showed only a minority of patients received necessary tests, highlighting the need for earlier detection.
Researchers have found that nearly 42% of ovarian cancer patient tumor tissues contain alterations in the protein km23. This discovery suggests km23 as a possible diagnostic indicator and therapeutic target for ovarian cancer. Further studies aim to develop a screening test and targeted therapies using km23.
A meta-analysis of epidemiological studies found a positive correlation between milk consumption and an increased risk of ovarian cancer. High intakes of dairy foods and lactose may contribute to this association, with a 13% increase in risk seen for every 10 grams of lactose consumed daily.
A study published in the International Journal of Cancer has found three proteins present in the blood of women with breast and ovarian cancer, but not in those without cancer. This breakthrough could lead to a simple blood test for early detection and improved patient outcomes.
Strong social attachments are associated with lower IL-6 levels, reduced mortality risk, and better quality of life among women with advanced ovarian cancer. Women with weak social connections have higher IL-6 levels, which promotes tumor growth and disease progression.
A study at the American Society of Clinical Oncology meeting found that a targeted cancer drug combined with low-dose chemotherapy shrinks ovarian cancer tumors in nearly half of patients. The treatment also slows disease progression and achieves stable disease in 59% of patients.
Researchers found a decreased risk of certain types of ovarian tumors with moderate recreational physical activity, but not others. Physical activity also regulates hormone and growth factor levels, reducing ovarian cancer risk by affecting obesity.
A study led by Daniel W. Cramer found that high blood levels of antibodies against MUC1 protein are associated with lower incidence of ovarian cancer. These events include bone fractures and gynecological surgeries, suggesting a potential link between immune system activation and cancer protection.
Researchers at Yale University have developed a new blood test for ovarian cancer screening using four biomarkers, showing high sensitivity and specificity. The test predicts cancer in patients whose levels of two or more biomarkers fall within a certain warning area.
A mathematical model suggests adjusting biometric identification systems can increase chances of catching known criminals at ports of entry by up to 94.9%. Human modification of Earth's water cycle through deforestation and irrigation may have regional impact on weather patterns and food production.
A study by Vanderbilt University researchers found that inhibiting COX-1 slowed the growth of epithelial ovarian tumors in a mouse model. This breakthrough suggests targeting COX-1 as a novel approach to prevent and treat ovarian cancer.
RAD001 targets mTOR enzyme in high-AKT activity ovarian cancer cells, arresting cell division and reducing angiogenesis. The treatment may be combined with chemotherapy to kill weakened cancer cells.
A study by Fox Chase Cancer Center researchers identified a subset of ovarian cancer patients who respond to Iressa, a targeted therapy. The team found that mutations in the EGFR tyrosine kinase portion of the receptor can make tumors more susceptible to the drug, potentially leading to improved treatment outcomes for some patients.
Researchers found that capsaicin, a compound in red chili pepper, exhibited anticancer activity against pancreatic cancer cells. Phenethyl isothiocyanate (PEITC), a constituent of cruciferous vegetables like broccoli, also showed therapeutic benefits in inhibiting ovarian cancer cell growth.
A clinical trial found that systematic aortic and pelvic lymphadenectomy improved progression-free survival, but not overall survival, in patients with advanced ovarian cancer. The procedure did not significantly increase median overall survival duration.
Researchers discovered that shape-altering genes, known for their role in embryonic development, direct ovarian cancer cells to take on various forms. These unique shapes make each form of ovarian cancer distinct from one another and the surface epithelium.
Women with a family history of breast or ovarian cancer are more likely to receive genetic counseling if they're white. African American women are less aware of genetic testing technology and underestimate their cancer risk. The study found a significant racial disparity in the use of BRCA1/2 testing, which is not explained by socioeco...
USC researchers found that the BRCA1 gene disrupts interactions between different cell types, leading to ovarian cancer. The gene's indirect action may lead to new treatment options by targeting a biochemical mediator.
A study by Yale University reveals that 0.8% of women with non-invasive breast cancer (DCIS) have BRCA1 mutations, while 2.4% have BRCA2 mutations, similar to those found in more advanced breast cancers. Women with these mutations are at higher risk for early detection and may benefit from high-risk screening protocols.
Researchers have found that a combination of surgery and intraperitoneal hyperthermic chemotherapy (IPHC) improves overall survival and quality of life in patients with tumors of the appendix, small bowel, ovarian cancer, colon, rectum, stomach, and mesothelioma. The treatment has been shown to be effective for high-grade and low-grade...
A study found that the experimental test's effectiveness was undermined by technical issues and biological implausibility, casting doubt on its potential as a reliable diagnostic tool. The researchers emphasize the need for standardized protocols in proteomics research to ensure reproducibility of results.
A new study found that blocking VEGFR-3 prevented lymphangiogenesis in a mouse model, potentially inhibiting tumor metastasis. The study suggests that targeting VEGFR-3 may be a viable therapeutic strategy to prevent lymphatic vessel growth and tumor spread.
Researchers from USC found evidence that progesterone signaling influences ovarian cancer risk, particularly two haplotypes (4-D and 4-E) that increase risk by almost 3.5-fold in women who carry them. The study's findings suggest that subtle changes in the progesterone receptor gene may decrease its efficiency, leading to ovarian cancer.
Researchers used gene expression profiling to develop a prognostic profile for ovarian cancer, identifying 115 genes that provide important information about prognosis. This technology holds promise for understanding the root causes of ovarian cancer and designing targeted therapies.
Urinary incontinence and abdominal pain are key symptoms of ovarian cancer, with crampy abdominal pain being the most common symptom. The study found that women often ignore or downplay these symptoms, leading to delayed diagnosis.
BRCA1 mutations are found in only 5% of breast and ovarian cancers, but loss-of-function mutations can significantly increase cancer risk. Researchers review preclinical and clinical evidence to determine if BRCA1 function can predict chemotherapy response, highlighting the need for prospective studies.
A large population study has found that most ovarian cancers in families with at least one woman with breast cancer are not related to BRCA1/2 mutations. Instead, other factors may contribute to the increased risk of ovarian cancer in these families.
A review of ovarian cancer treatment controversies highlights potential caveats in the current standard first-line therapy. The study suggests that optimal management questions remain, including the effectiveness of doublet platinum-cyclophosphamide and higher doses.
In a breakthrough procedure, doctors have successfully transplanted a healthy ovary from a patient's body into her upper arm, preserving her fertility. The innovative technique uses brachial vessels to establish blood supply and has shown promising results in maintaining cyclical follicular growth.
Dr. Lancaster's presentation at the IGCS conference used microarray analysis to predict response to platinum-based chemotherapy for advanced stage epithelial ovarian cancers. The study aimed to individualize therapy for patients with advanced ovarian cancer, showcasing Moffitt's expertise in gynecologic cancer research.
Research found ovarian cancer rates levelling across Europe, with declining incidence and mortality rates in northern countries, particularly among younger age groups. In contrast, southern and eastern European countries saw increasing cancer incidence and mortality rates.
IU researchers aim to capitalize on human genome data and powerful bioinformatics approaches to develop better therapies for ovarian and breast cancer patients. The study will focus on genetic and molecular consequences of DNA modifications to improve predictive models.
A new protein, Rab25, has been associated with increased aggressiveness in both breast and ovarian cancers. Low levels of Rab25 protein expression were found to be linked to better clinical outcomes, with patients experiencing higher survival rates when tumors expressed low levels of the protein.
A study of supportive-expressive group therapy for women with BRCA1 or 2 gene mutations found improvements in anxiety, depression, and decision-making. The therapy helped women weigh treatment choices by exploring feelings and perspectives.
A meta-analysis of RCT data found that patients receiving adjuvant chemotherapy had a lower risk of death and recurrence than those not receiving chemotherapy. Women with optimally staged stage I ovarian cancer may have an excellent prognosis without adjuvant chemotherapy.
Fox Chase Cancer Center researchers have identified hypermethylation of BRCA1 and RASSF1A genes as a potential target for detecting ovarian cancer in blood. The study found that 82% of patients with ovarian cancer had hypermethylated genes in their blood DNA, making it a promising diagnostic tool.
Researchers found that a blood test, CA125, was 2.6 times more accurate than CT scans in predicting patient survival. The study suggests that tumor-marker guided response criteria like CA125 may be superior to imaging-based response criteria in predicting treatment outcomes.
In a breakthrough study, researchers found that dendritic cells, a type of immune cell, can be co-opted by tumors to promote angiogenesis and tumor growth. The study suggests a new approach to fighting solid tumors by targeting the interaction between angiogenesis and the immune response.
Researchers identify three biomarkers from serum proteomic analysis that correctly identified 74% of early-stage ovarian cancers, improving detection capabilities. The test combines these markers with CA125 for enhanced accuracy.
Researchers found that ovarian cancer tumors lack response to antiestrogens due to decreased ER beta expression, which can lead to increased cell proliferation and apoptosis. The reintroduction of ER beta in cancer cells induced apoptosis, suggesting its regulatory functions in controlling ovarian cancer growth and motility.
Researchers have identified a potential biomarker for ovarian cancer using a blood test that accurately predicts the presence of the disease in 93% of cases. The study suggests that lysophospholipids, found in high levels in most ovarian cancer patients, may be used to develop an early detection strategy for this devastating disease.
Researchers are collecting blood samples from hundreds of women to validate the novel approach. The test has received worldwide attention due to its potential for early detection and high survival rates. If successful, it could save thousands of lives annually.
Researchers found that women with ovarian cancer typically experience symptoms 20-30 times per month and have more severe and recent-onset symptoms. In contrast, women with benign masses or controls have fewer and milder symptoms.
A study of 60 Korean women with breast cancer found a high rate of genetic mutations in BRCA1 and BRCA2 genes. The average age of diagnosis was 40-50 years old, which is younger than in the US population. The study suggests different genetic and environmental factors may be at play for Korean patients diagnosed at a young age.
A study by Johns Hopkins Medicine found that nearly half of ovarian cancer surgeries in Maryland were performed by low-volume surgeons, those with four or fewer cases per year. High-volume surgeons, who perform more than 10 cases per year, are more likely to accurately assess disease stage and increase survival rates.
The US Preventive Services Task Force recommends against routine ovarian cancer screening due to no evidence that it reduces mortality. In contrast, they support regular eye exams for children under 5 to detect amblyopia and other causes of visual impairment. Early detection can improve visual acuity and prevent long-term harm.
A recent study found that coronal reformatted images from 16-MDCT can change overall readings in 83% of cases with ovarian cancer. The study suggests that radiologists should view both axial and coronal images together to accurately stage the disease.
Researchers examined 45 primary ovarian carcinoma samples and found that 40% had decreased or complete loss of Rb2 protein expression. The study suggests Rb2's role in ovarian carcinogenesis and potential clinical applications for detecting and treating cancer.
A Medical College of Georgia study aims to identify specific protein markers in the blood that indicate how ovarian cancer responds to therapy. By analyzing changes in protein expression over time, researchers hope to develop a better understanding of the disease process and create more effective screening tests.